EU/3/08/561: Orphan designation for the prevention of graft-versus-host disease

Donor lymphocyte preparation depleted of functional alloreactive T-cells

Table of contents


On 5 September 2008, orphan designation (EU/3/08/561) was granted by the European Commission to Kiadis Pharma Netherlands B.V, Netherlands, for donor lymphocyte preparation depleted of functional alloreactive T-cells for the prevention of Graft-versus-Host disease.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Donor lymphocyte preparation depleted of functional alloreactive T-cells
Intended use
Prevention of graft-versus-host disease
Orphan designation status
EU designation number
Date of designation
Kiadis Pharma Netherlands B.V
Entrada 231-234
1096 EG Amsterdam
The Netherlands
Tel. +31 20 3140250
Fax +31 20 3140251

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating